医学
多发性骨髓瘤
细胞因子释放综合征
造血干细胞移植
内科学
肿瘤科
嵌合抗原受体
队列
入射(几何)
移植
临床试验
自体干细胞移植
胃肠病学
干细胞
骨髓
疾病
回顾性队列研究
免疫疗法
免疫系统
免疫学
外科
累积发病率
细胞疗法
抗体
总体生存率
抗原
挽救疗法
病理
造血
梅尔法兰
作者
Xin Li,Can Liu,Siyan Niu,Ru Li,Shuquan Gao,Rui Cui,Jia Wang,Yao Qi,Jingyi Li,Qi Deng
标识
DOI:10.1186/s12967-026-08302-y
摘要
BACKGROUND: Relapsed/refractory multiple myeloma (R/R MM) with extramedullary disease (EMD) has a poor prognosis. Responses to current therapies, including autologous hematopoietic stem cell transplantation (auto-HSCT) and chimeric antigen receptor (CAR) T-cell therapy, remain unsatisfactory or show frequent early progression despite an initial response. In this study, we aimed to investigate the efficacy of a therapeutic approach combining CAR T-therapy with auto-HSCT. METHODS: Eighteen patients with R/R MM with EMD were enrolled in clinical trials evaluating anti-BCMA CAR-T therapy. Of these, eight patients were treated in combination with auto-ASCT in combination (T-C group), while the remaining ten underwent CAR T-cell therapy alone (C group). We retrospectively compared the clinical responses, CAR T-cell expansion kinetics, T-cell subset profiles, serum interleukin-6 (IL-6) levels, treatment-related toxicities, and long-term outcomes between the two cohorts. RESULTS: In the T-C group, all 8 patients achieved an overall response (ORR) (ORR) based on the combined haematologic and imaging assessments of EMD. In contrast, among the 10 patients in the C group, 8 met the haematologic criteria for ORR, but only 6 demonstrated a radiographic response in EMD lesions. Progression-free survival (PFS) and overall survival (OS) were markedly improved in the T-C group. This cohort also exhibited higher peak levels of both CAR- T cells and IL-6. On day 28 post-infusion, the proportion of CD3⁺CD4⁺ T cells was significantly higher in the T-C group. While cytokine release syndrome (CRS) tended to be more severe in this group, the incidence and severity of the immune effector cell-associated neurotoxicity syndrome (ICANS) was comparable between the two groups. Haematologic recovery was delayed in the T-C group, and three of the eight patients developed poor graft function. CONCLUSION: We retrospectively summarised the results of a 3-year follow-up and found that the combination of anti-BCMA CAR-T cell therapy and auto-HSCT was associated with improved PFS and OS in R/R MM patients with EMD. Moreover, CD4⁺ T-cell dynamics may be associated with the durable clinical response observed in the T-C group. Although the T-C group experienced higher-grade CRS and prolonged haematological toxicity, no treatment-related deaths due to treatment-related toxicities were observed. (Trial registration: ChiCTR2000033925). TRIAL REGISTRATION: Registration center: Tianjin First Central Hospital. TRIAL REGISTRATION NUMBER: ChiCTR2000033925. Registration Date: June 17, 2020. The patient gave their written informed consent in accordance with the Declaration of Helsinki. The patients agreed to have their data used in our study.
科研通智能强力驱动
Strongly Powered by AbleSci AI